Novo Nordisk says Alzheimer’s drug trial fails to meet main goal

Novo Nordisk’s shares fell 10% after the company said its oral semaglutide drug Rybelsus failed to meet the main goal in late-stage trials testing whether it could slow cognitive decline in early Alzheimer’s patients. The setback dims hopes for expanding GLP-1 medicines into a major new market beyond obesity and diabetes, reinforcing scepticism over Novo’s […]
Will Americans ever be able to afford weight loss drugs?

For nearly two years Nicole Cowart’s doctor recommended she take a glucagon-like peptide-1 (GLP-1) receptor agonist. The doctor said it would help her manage her prediabetes and leg swelling—but her insurance wouldn’t pay unless she was diagnosed with type 2 diabetes.Cowart ran out of treatment options and remembers her doctor hoping that she would develop […]
Muscly people show slower brain ageing, study finds

Research highlights possible drawback of muscle mass loss through use of GLP-1 anti-obesity drugs
24th November – Threat Intelligence Report

For the latest discoveries in cyber research for the week of 24th November, please download our Threat Intelligence Bulletin. Introduction to Malware Binary Triage (IMBT) Course Looking to level up your skills? Get 10% off using coupon code: MWNEWS10 for any flavor. Enroll Now and Save 10%: Coupon Code MWNEWS10 Note: Affiliate link – your […]
GLP-1 side effects – LAist

GLP-1 side effects LAist Brain scientists are seeking weight-loss drugs without the nausea : Shots – Health News NPR Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide Nature Better Than Ozempic? New Oxytocin Combination Could Eliminate Side Effects SciTechDaily GLP-1 Drug May Offer Short-Term Control of Obsessive Food Cravings U.S. News & World Report
GLP-1 Receptor Agonists Linked to Lower Infection Risk

GLP-1 receptor agonists are associated with a lower risk for serious infections, a recent meta-analysis suggests. Medscape Medical News
People taking weight loss jabs could be at risk of pancreas issues

GLP-1 medicines, such as tirzepatide (Mounjaro) and semaglutide (Wegovy) work by making people feel fuller for longer
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trials

Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay disease progression in patients in two …
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression

Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as […]
UBS sees 60% more upside in Shaily Engineering after a massive 700% rally in two years. Here’s why

UBS has initiated coverage of Shaily Engineering Plastics with a ‘Buy’ rating and a target price of ₹4,000, indicating a 60% upside. The firm highlights Shaily’s patented technology and strong market position for GLP-1 therapies, estimating substantial revenue growth and a 75% EPS CAGR by FY28.